Updates with Citi, Jefferies notes

** Shares of Telix Pharmaceuticals TLX.AX rise as much as 4.2% to A$15.73, their largest intraday pct jump since July 6

** The biopharma major logs 2Q26 revenue of $247 million, up 21% from last year

** Also sees FY26 revenue and other income in excess of $1 billion

** We expect this could push FY26 consensus up low-single-digits but could also raise some questions around the phasing of growth across quarters - Citi

** Jefferies raises price target for company to A$29 per share from A$27.40; sees potential for meaningful upside should its products be approved

** Stock up 37.3% YTD, including the day's moves